• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于 siRNA 递送的基于脂质的纳米治疗剂。

Lipid-based nanotherapeutics for siRNA delivery.

机构信息

Department of Chemical Engineering and David H. Koch Institute of Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.

出版信息

J Intern Med. 2010 Jan;267(1):9-21. doi: 10.1111/j.1365-2796.2009.02189.x.

DOI:10.1111/j.1365-2796.2009.02189.x
PMID:20059641
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5308083/
Abstract

RNA interference (RNAi) is a specific gene-silencing mechanism triggered by small interfering RNA (siRNA). The application of RNAi in the clinic requires the development of safe and effective delivery systems. Inspired by progress with lipid-based systems in drug delivery, efforts have been dedicated to the development of liposomal siRNA delivery systems. Many of the lipid-based delivery vehicles self-assemble with siRNA through electrostatic interactions with charged amines, generating multi-lamellar lipoplexes with positively charged lipid bilayers separated from one another by sheets of negatively charged siRNA strands. Internalization of lipid-based siRNA delivery systems into cells typically occurs through endocytosis; accordingly, delivery requires materials that can facilitate endosomal escape. The size of the carrier is important as carriers <100 nm in diameter have been reported to have higher accumulation levels in tumours, hepatocytes and inflamed tissue, whereas larger particles tend to be taken up by Kupffer cells or other components of the reticuloendothelial system (RES). To reduce RES uptake and increase circulation time, carriers have been modified on the surface with hydrophilic materials, such as polyethyleneglycol. Herein, we review the molecular and structural parameters of lipid-based siRNA delivery systems.

摘要

RNA 干扰 (RNAi) 是一种由小干扰 RNA (siRNA) 触发的特定基因沉默机制。RNAi 在临床上的应用需要开发安全有效的递送系统。受脂质体药物递送系统进展的启发,人们致力于开发脂质体 siRNA 递送系统。许多基于脂质的递送载体通过与带电荷的胺的静电相互作用与 siRNA 自组装,生成多层层状脂质体复合物,带正电荷的脂质双层彼此分离,由带负电荷的 siRNA 链组成。基于脂质的 siRNA 递送系统进入细胞的内化通常通过内吞作用发生;因此,递送需要能够促进内涵体逃逸的材料。载体的大小很重要,因为据报道,直径 <100nm 的载体在肿瘤、肝细胞和炎症组织中的积累水平更高,而较大的颗粒往往被库普弗细胞或网状内皮系统 (RES) 的其他成分摄取。为了减少 RES 的摄取并增加循环时间,载体的表面已用亲水性材料(如聚乙二醇)进行了修饰。在此,我们综述了基于脂质的 siRNA 递送系统的分子和结构参数。

相似文献

1
Lipid-based nanotherapeutics for siRNA delivery.用于 siRNA 递送的基于脂质的纳米治疗剂。
J Intern Med. 2010 Jan;267(1):9-21. doi: 10.1111/j.1365-2796.2009.02189.x.
2
Nanomedicine based approaches for the delivery of siRNA in cancer.基于纳米医学的方法实现 siRNA 在癌症中的递送。
J Intern Med. 2010 Jan;267(1):44-53. doi: 10.1111/j.1365-2796.2009.02191.x.
3
Multifunctional pH-Sensitive Amino Lipids for siRNA Delivery.用于 siRNA 递送的多功能 pH 敏感氨基脂质
Bioconjug Chem. 2016 Jan 20;27(1):19-35. doi: 10.1021/acs.bioconjchem.5b00538. Epub 2015 Dec 17.
4
Delivery of siRNA Complexed with Palmitoylated α-Peptide/β-Peptoid Cell-Penetrating Peptidomimetics: Membrane Interaction and Structural Characterization of a Lipid-Based Nanocarrier System.与棕榈酰化α-肽/β-拟肽细胞穿透肽模拟物复合的小干扰RNA的递送:基于脂质的纳米载体系统的膜相互作用和结构表征
Mol Pharm. 2016 Jun 6;13(6):1739-49. doi: 10.1021/acs.molpharmaceut.5b00309. Epub 2016 May 9.
5
A novel mechanism is involved in cationic lipid-mediated functional siRNA delivery.一种新机制参与阳离子脂质介导的功能性小干扰RNA递送。
Mol Pharm. 2009 May-Jun;6(3):763-71. doi: 10.1021/mp900023v.
6
Effect of the nanoformulation of siRNA-lipid assemblies on their cellular uptake and immune stimulation.小干扰RNA-脂质组装体纳米制剂对其细胞摄取和免疫刺激的影响。
Int J Nanomedicine. 2017 Jul 19;12:5121-5133. doi: 10.2147/IJN.S136426. eCollection 2017.
7
Lipid-based Vehicles for siRNA Delivery in Biomedical Field.用于生物医学领域 siRNA 递送的脂质载体。
Curr Pharm Biotechnol. 2020;21(1):3-22. doi: 10.2174/1389201020666190924164152.
8
siRNA delivery to lung-metastasized tumor by systemic injection with cationic liposomes.通过阳离子脂质体全身注射将小干扰RNA递送至肺转移瘤。
J Liposome Res. 2015;25(4):279-86. doi: 10.3109/08982104.2014.992024. Epub 2015 Sep 4.
9
Modulated cellular delivery of anti-VEGF siRNA (bevasiranib) by incorporating supramolecular assemblies of hydrophobically modified polyamidoamine dendrimer in stealth liposomes.通过将疏水性修饰的聚酰胺胺树枝状大分子的超分子组装体包封在隐形脂质体中,实现了抗 VEGF siRNA(bevasiranib)的调制细胞递送。
Int J Pharm. 2016 Aug 20;510(1):30-41. doi: 10.1016/j.ijpharm.2016.06.026. Epub 2016 Jun 10.
10
Technologies for investigating the physiological barriers to efficient lipid nanoparticle-siRNA delivery.用于研究脂质纳米颗粒-siRNA 递送达有效率的生理障碍的技术。
J Histochem Cytochem. 2013 Jun;61(6):407-20. doi: 10.1369/0022155413484152. Epub 2013 Mar 14.

引用本文的文献

1
Targeting tumor immune evasion: the role of PD-L1 siRNA in advancing cancer immunotherapy.靶向肿瘤免疫逃逸:PD-L1小干扰RNA在推进癌症免疫治疗中的作用
Med Oncol. 2025 Sep 13;42(11):471. doi: 10.1007/s12032-025-03025-4.
2
Promoter-targeted small RNA duplexes increase MBNL1 transcription and mitigate myotonic dystrophy-associated spliceopathy.启动子靶向小RNA双链体增加MBNL1转录并减轻强直性肌营养不良相关的剪接异常。
Nucleic Acids Res. 2025 Aug 11;53(15). doi: 10.1093/nar/gkaf756.
3
Intracellular fatty acid levels differentially impact target silencing by FDA-approved siRNA drugs.细胞内脂肪酸水平对FDA批准的小干扰RNA(siRNA)药物的靶点沉默有不同影响。
Biochem Pharmacol. 2025 Jul 27;242(Pt 2):117192. doi: 10.1016/j.bcp.2025.117192.
4
Multiparametric functional characterization of individual lipid nanoparticles using surface-sensitive light-scattering microscopy.使用表面敏感光散射显微镜对单个脂质纳米颗粒进行多参数功能表征。
Proc Natl Acad Sci U S A. 2025 May 27;122(21):e2426601122. doi: 10.1073/pnas.2426601122. Epub 2025 May 22.
5
Recent Update on siRNA Therapeutics.小干扰RNA疗法的最新进展
Int J Mol Sci. 2025 Apr 8;26(8):3456. doi: 10.3390/ijms26083456.
6
Co-delivery of antioxidants and siRNA-VEGF: promising treatment for age-related macular degeneration.抗氧化剂与 siRNA-VEGF 的共同递送:年龄相关性黄斑变性的有前景的治疗方法。
Drug Deliv Transl Res. 2025 Jan 3. doi: 10.1007/s13346-024-01772-x.
7
Effect of Cinnamaldehyde and Its Nanoemulsion on Acanthamoeba castellanii Cysts and Trophozoites.肉桂醛及其纳米乳剂对卡氏棘阿米巴包囊和滋养体的影响。
Acta Parasitol. 2025 Jan 3;70(1):1. doi: 10.1007/s11686-024-00938-4.
8
Therapeutic effect of E-Lip-siRNA-sFlt1 on pre-eclampsia: targeted gene silencing and improved pregnancy outcomes.E-Lip-siRNA-sFlt1 对子痫前期的治疗作用:靶向基因沉默和改善妊娠结局。
Nanomedicine (Lond). 2024;19(18-20):1615-1627. doi: 10.1080/17435889.2024.2368449. Epub 2024 Jul 17.
9
The Impact of Chemical Modifications on the Interferon-Inducing and Antiproliferative Activity of Short Double-Stranded Immunostimulating RNA.化学修饰对短双链免疫刺激 RNA 的干扰素诱导和抗增殖活性的影响。
Molecules. 2024 Jul 7;29(13):3225. doi: 10.3390/molecules29133225.
10
Experimental Infection Models and Their Usefulness for White Spot Syndrome Virus (WSSV) Research in Shrimp.实验感染模型及其在虾类白斑综合征病毒(WSSV)研究中的应用。
Viruses. 2024 May 20;16(5):813. doi: 10.3390/v16050813.

本文引用的文献

1
Magnetic Iron Oxide Nanoworms for Tumor Targeting and Imaging.用于肿瘤靶向和成像的磁性氧化铁纳米蠕虫
Adv Mater. 2008 May 5;20(9):1630-1635. doi: 10.1002/adma.200800004.
2
Pegylated nanoliposomes remote-loaded with the antioxidant tempamine ameliorate experimental autoimmune encephalomyelitis.负载抗氧化剂替马明的聚乙二醇化纳米脂质体远程装载可改善实验性自身免疫性脑脊髓炎。
J Neuroimmunol. 2009 Aug 18;213(1-2):20-5. doi: 10.1016/j.jneuroim.2009.05.019. Epub 2009 Jun 28.
3
Combination therapy using the small interfering RNA bevasiranib.使用小干扰RNA贝伐西拉尼的联合疗法。
Retina. 2009 Jun;29(6 Suppl):S49-50. doi: 10.1097/IAE.0b013e3181ad2341.
4
RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy.RNA干扰介导的呼吸道合胞病毒核衣壳沉默定义了一种有效的抗病毒策略。
Antimicrob Agents Chemother. 2009 Sep;53(9):3952-62. doi: 10.1128/AAC.00014-09. Epub 2009 Jun 8.
5
Synthetic methylated CpG ODNs are potent in vivo adjuvants when delivered in liposomal nanoparticles.合成甲基化CpG寡脱氧核苷酸通过脂质体纳米颗粒递送时,是有效的体内佐剂。
Int Immunol. 2009 Jul;21(7):757-67. doi: 10.1093/intimm/dxp044. Epub 2009 Jun 5.
6
siRNA for inflammatory diseases.用于炎症性疾病的小干扰RNA
Curr Opin Investig Drugs. 2009 May;10(5):418-24.
7
A novel mechanism is involved in cationic lipid-mediated functional siRNA delivery.一种新机制参与阳离子脂质介导的功能性小干扰RNA递送。
Mol Pharm. 2009 May-Jun;6(3):763-71. doi: 10.1021/mp900023v.
8
The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic.首次通过基于环糊精聚合物的自组装纳米颗粒在人体中实现小干扰RNA的靶向递送:从概念到临床应用。
Mol Pharm. 2009 May-Jun;6(3):659-68. doi: 10.1021/mp900015y.
9
Development of lipidoid-siRNA formulations for systemic delivery to the liver.用于全身递送至肝脏的脂质体-siRNA制剂的研发。
Mol Ther. 2009 May;17(5):872-9. doi: 10.1038/mt.2009.36. Epub 2009 Mar 3.
10
Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice.在小鼠中证实基于小干扰RNA的癌症治疗药物的RNA干扰介导的作用机制。
J Clin Invest. 2009 Mar;119(3):661-73. doi: 10.1172/JCI37515. Epub 2009 Feb 23.